Kodiak Sciences Inc. (KOD)
| Market Cap | 2.03B +180.6% |
| Revenue (ttm) | n/a |
| Net Income | -241.99M |
| EPS | -4.18 |
| Shares Out | 62.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,277,335 |
| Open | 33.03 |
| Previous Close | 33.22 |
| Day's Range | 31.00 - 33.71 |
| 52-Week Range | 10.94 - 47.84 |
| Beta | 2.18 |
| Analysts | Strong Buy |
| Price Target | 69.60 (+115.15%) |
| Est. Earnings | Nov 12, 2026 |
About KOD
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic mac... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for KOD stock is "Strong Buy." The 12-month stock price target is $69.6, which is an increase of 115.15% from the latest price.
News
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Kodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time PALO ALTO, Calif., Sept. 25, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused bio...
Kodiak Sciences resumed with a Neutral at Goldman Sachs
Goldman Sachs resumed coverage of Kodiak Sciences (KOD) with a Neutral rating and $36 price target Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform…
3 Best Stocks With 75%+ Upside to Buy This Week, According to Analysts
Analysts see strong momentum in some stocks this week, including Kodiak Sciences ($KOD), Archer Aviation ($ACHR), and CleanSpark ($CLSK). While each stock carries risk, analysts believe all three have...
Kodiak Sciences reports Q2 EPS ($1.05), consensus (96c)
Ended Q2 with $125.9M of cash and cash equivalents, expects that current cash and cash equivalents will support current and planned operations into 2027. “Kodiak continues to execute broadly across…
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
PALO ALTO, Calif., Aug. 13, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026.
Kodiak Sciences Earnings release: Q2 2026
Kodiak Sciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Kodiak Sciences Quarterly report: Q2 2026
Kodiak Sciences has published its Q2 2026 quarterly earnings report on August 13, 2026.
Kodiak enrolls first patients in phase 3 ALTO trial evaluating KSI-501
Kodiak Sciences (KOD) announces the first patients have been enrolled in the global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic macular edema, or DME. KSI-501 is an…
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema PALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasd...
Kodiak Sciences completes enrollment in first cohort of Phase 3 PEAK trial
Kodiak Sciences (KOD) announced that it has completed enrollment of the first 300-patient cohort in its PEAK trial, supporting Pivotal Analysis 1 of the KSI-101 Phase 3 program in macular…
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
First pivotal cohort enrolled 300 subjects, with topline clinical data from 24-week primary endpoint on track for December 2026 release Completion of enrollment in the second pivotal cohort evaluating...
Kodiak Sciences price target raised to $66 from $56 at JPMorgan
JPMorgan raised the firm’s price target on Kodiak Sciences (KOD) to $66 from $56 and keeps an Overweight rating on the shares. The company is expected in Q3 to report…
Kodiak Sciences Transcript: Jefferies Global Healthcare Conference 2026
Three late-stage retinal therapies are advancing, with pivotal phase III data expected in late 2024 and 2026. Zenkuda and KSI-501 aim to combine rapid efficacy with extended durability, while KSI-101 targets a large unmet need in MESI. Multiple BLA filings and potential approvals are anticipated by 2027.
Kodiak Sciences Slides: FY 2026
Kodiak Sciences has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 4, 2026.
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transf...
Kodiak Sciences upgraded to Buy from Neutral at Chardan
Chardan upgraded Kodiak Sciences (KOD) to Buy from Neutral with a $61 price target “Stellar results” from GLOW2, supported by enthusiasm among key opinion leaders with whom the firm spoke…
Kodiak Sciences reports Q1 EPS (94c), consensus ($1.01)
Kodiak ended Q1 with $169.5M cash and cash equivalents and believes that current cash and cash equivalents will support operations into 2027. “Kodiak has entered 2026 with continued momentum and…
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.
Kodiak Sciences Earnings release: Q1 2026
Kodiak Sciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Kodiak Sciences Quarterly report: Q1 2026
Kodiak Sciences has published its Q1 2026 quarterly earnings report on May 7, 2026.
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supp...
Kodiak Sciences Proxy statement: Proxy filing
Kodiak Sciences filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Kodiak Sciences Proxy statement: Proxy filing
Kodiak Sciences filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Kodiak Sciences falls -8.7%
Kodiak Sciences (KOD) is down -8.7%, or -$3.72 to $39.09.
Kodiak Sciences Stock (KOD) Rallies as Analysts Weigh In After Earnings
Kodiak Sciences stock climbed on Wednesday alongside analyst updates after the company’s most recent earnings report.